This gap remains despite recent progress in benefiting patients with various subtypes of AML through targeted therapies, such as hypomethylating agents, immune checkpoint inhibitors, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors [7, 8]. This evidence concerns the gene FLT3 and acute myeloid leukemia.